Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|August 18, 2017

ISPE European Conference Announces Pharma 4.0

The International Society for Pharmaceutical Engineering (ISPE) announced its Europe Pharma 4.0 Conference, taking place November 23 – 24, 2017 in Verona, Italy.

The International Society for Pharmaceutical Engineering (ISPE) announced its Europe Pharma 4.0 Conference, taking place November 23 – 24, 2017 in Verona, Italy. Organized in partnership with the ISPE Italy Affiliate, the conference will focus on preparing the pharmaceutical and biopharmaceutical industry for a full transition to an end-to-end integrated computerized system throughout the manufacturing process.

Founded by the ISPE Europe Affiliates’ special interest group (SIG), From Industry 4.0 to Pharma 4.0, the two-day event features an education program focused on core topics, including automation, analytics, end-to-end integration, and workforce 4.0. Attendees will gain insight into a new world of manufacturing, engage in dialogue with peer groups and senior industry leaders, and learn new manufacturing applications, models, and solutions

“Shifting the paradigm to Pharma 4.0 and focusing on the issues specifically surrounding pharmaceutical priorities will lead to improvements in productivity, quality, and security of the supply chain,” said John Bournas, ISPE CEO and president, in a company press release. “The conference will explore the effects of this shift and how the industry will prepare for this next generational challenge.”

Source: ISPE


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.